vs
COLLEGIUM PHARMACEUTICAL, INC（COLL）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
COLLEGIUM PHARMACEUTICAL, INC的季度营收约是BRC Group Holdings, Inc.的1.1倍（$205.4M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs 8.3%，领先39.7%），COLLEGIUM PHARMACEUTICAL, INC同比增速更快（12.9% vs -21.9%），过去两年COLLEGIUM PHARMACEUTICAL, INC的营收复合增速更高（19.1% vs -15.4%）
Collegium制药是一家专科制药企业，专注于研发和商业化具备滥用威慑特性的创新疼痛管理疗法，主要面向美国市场，推出适用于慢性疼痛患者的缓释镇痛产品，服务覆盖基层及专科医疗领域的医护人员。
COLL vs RILY — 直观对比
营收规模更大
COLL
是对方的1.1倍
$188.3M
营收增速更快
COLL
高出34.8%
-21.9%
净利率更高
RILY
高出39.7%
8.3%
两年增速更快
COLL
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $205.4M | $188.3M |
| 净利润 | $17.0M | $90.3M |
| 毛利率 | 62.5% | 79.5% |
| 营业利润率 | 29.6% | 32.3% |
| 净利率 | 8.3% | 47.9% |
| 营收同比 | 12.9% | -21.9% |
| 净利润同比 | 35.3% | 1710.8% |
| 每股收益（稀释后） | $0.48 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COLLRILY
| Q4 25 | $205.4M | $188.3M | ||
| Q3 25 | $209.4M | $215.3M | ||
| Q2 25 | $188.0M | $188.2M | ||
| Q1 25 | $177.8M | $197.2M | ||
| Q4 24 | $181.9M | $241.0M | ||
| Q3 24 | $159.3M | $225.5M | ||
| Q2 24 | $145.3M | $256.0M | ||
| Q1 24 | $144.9M | $263.4M |
净利润COLLRILY
| Q4 25 | $17.0M | $90.3M | ||
| Q3 25 | $31.5M | $91.1M | ||
| Q2 25 | $12.0M | $139.5M | ||
| Q1 25 | $2.4M | $-10.0M | ||
| Q4 24 | $12.5M | $-5.6M | ||
| Q3 24 | $9.3M | $-284.4M | ||
| Q2 24 | $19.6M | $-433.6M | ||
| Q1 24 | $27.7M | $-49.2M |
毛利率COLLRILY
| Q4 25 | 62.5% | 79.5% | ||
| Q3 25 | 61.7% | 83.7% | ||
| Q2 25 | 57.7% | 81.3% | ||
| Q1 25 | 54.8% | 81.4% | ||
| Q4 24 | 54.0% | 79.8% | ||
| Q3 24 | 60.8% | 82.1% | ||
| Q2 24 | 62.5% | 84.5% | ||
| Q1 24 | 63.1% | 85.3% |
营业利润率COLLRILY
| Q4 25 | 29.6% | 32.3% | ||
| Q3 25 | 29.7% | 30.4% | ||
| Q2 25 | 18.7% | 5.7% | ||
| Q1 25 | 12.2% | -31.2% | ||
| Q4 24 | 20.9% | -69.2% | ||
| Q3 24 | 21.9% | -36.4% | ||
| Q2 24 | 32.7% | -90.8% | ||
| Q1 24 | 34.1% | -6.1% |
净利率COLLRILY
| Q4 25 | 8.3% | 47.9% | ||
| Q3 25 | 15.0% | 42.3% | ||
| Q2 25 | 6.4% | 74.1% | ||
| Q1 25 | 1.4% | -5.1% | ||
| Q4 24 | 6.9% | -2.3% | ||
| Q3 24 | 5.9% | -126.1% | ||
| Q2 24 | 13.5% | -169.4% | ||
| Q1 24 | 19.1% | -18.7% |
每股收益（稀释后）COLLRILY
| Q4 25 | $0.48 | $2.78 | ||
| Q3 25 | $0.84 | $2.91 | ||
| Q2 25 | $0.34 | $4.50 | ||
| Q1 25 | $0.07 | $-0.39 | ||
| Q4 24 | $0.36 | $-0.01 | ||
| Q3 24 | $0.27 | $-9.39 | ||
| Q2 24 | $0.52 | $-14.35 | ||
| Q1 24 | $0.71 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $386.7M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $301.7M | $-171.5M |
| 总资产 | $1.7B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资COLLRILY
| Q4 25 | $386.7M | $226.6M | ||
| Q3 25 | $285.9M | $184.2M | ||
| Q2 25 | $222.2M | $267.4M | ||
| Q1 25 | $197.8M | $138.3M | ||
| Q4 24 | $162.8M | $146.9M | ||
| Q3 24 | $120.0M | $159.2M | ||
| Q2 24 | $271.6M | $236.9M | ||
| Q1 24 | $318.0M | $190.7M |
总债务COLLRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益COLLRILY
| Q4 25 | $301.7M | $-171.5M | ||
| Q3 25 | $274.8M | $-260.5M | ||
| Q2 25 | $232.2M | $-351.7M | ||
| Q1 25 | $234.4M | $-496.8M | ||
| Q4 24 | $228.8M | $-488.2M | ||
| Q3 24 | $234.3M | $-497.6M | ||
| Q2 24 | $216.6M | $-218.3M | ||
| Q1 24 | $222.2M | $228.4M |
总资产COLLRILY
| Q4 25 | $1.7B | $1.7B | ||
| Q3 25 | $1.6B | $1.7B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.7B | $1.8B | ||
| Q3 24 | $1.6B | $2.2B | ||
| Q2 24 | $1.1B | $3.2B | ||
| Q1 24 | $1.1B | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $123.0M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $122.4M | — |
| 自由现金流率自由现金流/营收 | 59.6% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | 7.25× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $327.6M | — |
8季度趋势，按日历期对齐
经营现金流COLLRILY
| Q4 25 | $123.0M | $26.2M | ||
| Q3 25 | $78.4M | $-60.6M | ||
| Q2 25 | $72.4M | $-25.6M | ||
| Q1 25 | $55.4M | $184.0K | ||
| Q4 24 | $84.6M | $-2.7M | ||
| Q3 24 | $-9.0M | $19.5M | ||
| Q2 24 | $67.4M | $111.5M | ||
| Q1 24 | $61.9M | $135.4M |
自由现金流COLLRILY
| Q4 25 | $122.4M | — | ||
| Q3 25 | $78.3M | — | ||
| Q2 25 | $72.4M | — | ||
| Q1 25 | $54.6M | — | ||
| Q4 24 | $84.1M | — | ||
| Q3 24 | $-9.2M | — | ||
| Q2 24 | $67.1M | — | ||
| Q1 24 | $61.4M | — |
自由现金流率COLLRILY
| Q4 25 | 59.6% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 38.5% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 46.2% | — | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 42.3% | — |
资本支出强度COLLRILY
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.4% | — |
现金转化率COLLRILY
| Q4 25 | 7.25× | 0.29× | ||
| Q3 25 | 2.49× | -0.66× | ||
| Q2 25 | 6.05× | -0.18× | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COLL
暂无分部数据
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
